These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19028360)

  • 1. Anti-resorptives in the management of osteoporosis.
    Miller PD
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
    Seeman E
    Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring pharmacological therapy for osteoporosis.
    Lewiecki EM
    Rev Endocr Metab Disord; 2010 Dec; 11(4):261-73. PubMed ID: 20143165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of osteoporotic fracture by pharmaceutical interventions].
    Nakamura T
    Clin Calcium; 2006 Dec; 16(12):1961-67. PubMed ID: 17142925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
    Lyritis GP; Georgoulas T; Zafeiris CP
    Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
    Shiraki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
    Geoffroy V; Paschalis EP; Libouban H; Blouin S; Ostertag A; Chappard D; Cros M; Phipps R; de Vernejoul MC
    Calcif Tissue Int; 2011 Jun; 88(6):464-75. PubMed ID: 21455736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological diversity among drugs that inhibit bone resorption.
    Russell RG
    Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.